Chromos to acquire CellExSys. As per the deal, CellExSys shareholders will receive 1.5 M Chromos common shares in addition to a convertible debenture of CDN$3.375 M to be repaid either in cash or by issuance of Chromos shares. Chromos will also obtain CellExSys’ T-cell technology for cell therapy.